RGCNasdaqMedicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026
$10.05+0.46 (+4.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Regencell Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Market Cap | $4.97B | $166.30M |
| Enterprise Value | $4.96B | $88.19M |
| PB Ratio | 372.27 | 2.03 |
| P/TBV Ratio | 372.27 | 2.29 |
Income (trailing twelve months)
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Operating Income | -$11.72M | -$21.40M |
| Pretax Income | -$11.70M | -$14.34M |
| Net Income | -$11.70M | -$22.46M |
| EBITDA | -$11.72M | -$16.91M |
| EPS (Diluted) | -$2.37 | -$0.83 |
Returns
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -128.5% | -53.2% |
| Return on Assets (ROA) | -114.2% | -40.9% |
| Return on Capital Employed (ROCE) | -87.4% | -38.1% |
Balance sheet
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $14.19M | $61.43M |
| Net Cash (Debt) | $14.19M | $15.35M |
| Net Cash Per Share | $0.03 | $0.66 |
| Equity (Book Value) | $13.35M | $49.09M |
| Book Value Per Share | $0.03 | $1.37 |
| Tangible Book Value | $13.35M | $23.52M |
| Working Capital | $12.90M | $76.81M |
Financial position
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Current Ratio | 10.77 | 3.34 |
| Quick Ratio | 10.75 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.70M | -$12.35M |
Efficiency
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Profits Per Employee | -$900.15K | -$703.34K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -0.24% | -23.3% |
| Buyback Yield | -0.37% | -0.59% |
| Shareholder Yield | -0.37% | 0.00% |
Shares
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 494,489,000 | 58,127,000 |
| Shares Change (YoY) | 0.02% | 10.9% |
| Float | 55,407,200 | 49,136,700 |
| Shares Held by Insiders | 88.8% | 11.6% |
Scores
| Measure | Regencell Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | 2155.31 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Regencell Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.